TAKE financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹30.4crNo figure a year before
Net profit
₹1.1cr−₹0.9 cr in Q1 FY26
EBITDA margin
−0.9%No figure a year before
EPS
₹0.07−₹0.06 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue30.40.0—
EBITDA−0.3−0.8—
EBITDA margin−0.9%——
Profit before tax1.1−0.9—
Net profit1.1−0.9—
EPS₹0.07−₹0.06—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹30.4 crNet profit₹1.1 crNet margin3.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
156————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.30.33.40.810.7
0.00.00.00.0—
0.00.00.028.033.3
156————
84.654.20.065.6189
——−100.0%−65.3%—
−1.7−1.9−7.5−13.5−19.0
−2.0%−3.5%—−20.5%−10.1%
−1.7−1.9−7.5−21.3−35.9
12.810.837.5−120−100
15.2%20.0%—−182.3%−53.1%
₹0.87₹0.73₹2.53−₹8.09−₹6.78
—−71.0%+131.3%−19.3%—
—−4.1−16.49.320.0
—0.00.0−7.9−7.8
−4.1−4.1−16.41.412.2
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TAKE₹10.54

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹156 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————155.9
- Cash, Equiv & ST Investments10.70.83.40.30.3
+ Minority Interest—0.00.00.00.0
+ Total Debt33.328.00.00.00.0
Enterprise Value————155.7
Revenue189.165.60.054.284.6
Growth %, YoY—-65.3-100.0——
EBITDA-19.0-13.5-7.5-1.9-1.7
Margin %-10.07-20.54—-3.53-2.05
EBIT-35.9-21.3-7.5-1.9-1.7
Net Income-100.4-119.637.510.812.8
Margin %-53.08-182.33—20.0215.16
EPS, Adj (current shares)-6.78-8.092.530.730.87
Growth %, YoY—-19.3+131.3-71.0—
Cash from Operations20.09.3-16.4-4.1—
Capital Expenditures-7.8-7.9-0.0-0.0—
Free Cash Flow12.21.4-16.4-4.1-4.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

TAKE financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

TAKE (NSE: TAKE) had a market capitalisation of ₹164 crore at the 29 October 2026 close (₹11.06 a share), a PE ratio of 12.8 on the last four quarters' profit and a price-to-book ratio of 5.28. In FY26 its consolidated net profit was ₹10.8 crore on revenue of ₹54.2 crore; in Q1 FY27 (April–June 2026) it was ₹1.1 crore. It had no borrowings on 31 March 2026.

TAKE Q1 FY27 results
filed 11 August 2026
Share price used
₹11.06 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

TAKE at a glance · consolidated

Market cap
₹164 Crat ₹11.06 · 29 Oct close
PE ratio (last 4 quarters)
12.815.1 on FY26 profit
Price to book (PB)
5.28book value ₹2.10 a share
ROE (FY26)
42.1%ROCE −7.5%
Debt to equity
0.00net cash ₹28 lakh
FII holding
0.21%unchanged vs 30 Jun 2026no promoter group
Net worth
₹31 Cr+51.0% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹4.1 Cr
EPS (FY26)
₹0.74

Questions

What is the TAKE PE ratio today?

TAKE's PE ratio is 12.8 at the 29 October 2026 close (₹11.06 a share): a market capitalisation of ₹164 crore divided by consolidated net profit of ₹12.8 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹10.8 crore) it is 15.1.

What is the TAKE net worth?

TAKE's net worth — shareholders' equity in its consolidated balance sheet — was ₹31 crore on 31 March 2026, up 51.0% from ₹20.5 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹164 crore at the 29 October 2026 close.

What is the TAKE book value per share?

TAKE's book value per share was ₹2.10 on 31 March 2026: shareholders' equity of ₹31 crore divided by the 14.79 crore shares in issue, up 49.3% from ₹1.40 a year earlier. The share price at the 29 October 2026 close was ₹11.06.

What is the TAKE PB ratio (price to book value)?

TAKE's price-to-book (PB) ratio is 5.28 at the 29 October 2026 close: a market capitalisation of ₹164 crore divided by shareholders' equity (book value) of ₹31 crore on 31 March 2026. That is a book value of ₹2.10 per share against a share price of ₹11.06.

What is the TAKE ROE and ROCE?

In FY26, TAKE's return on equity (ROE) was 42.1% and its return on capital employed (ROCE) was −7.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).

What is the TAKE promoter holding?

TAKE has no promoter group: on 30 September 2026 promoters held 0% of its shares, according to the shareholding pattern filed with NSE. Foreign portfolio investors held 0.21% and domestic institutions 0.00%.

What is the TAKE market cap?

TAKE's market capitalisation was ₹164 crore at the 29 October 2026 close: 14.79 crore shares at ₹11.06 each.

Is TAKE debt free?

Yes. TAKE had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹28 lakh of cash, bank balances and current investments.

What is the TAKE debt to equity ratio?

TAKE's debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹31 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the TAKE EPS?

TAKE's basic earnings per share (EPS) were ₹0.74 in FY26, against ₹2.56 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹0.86.

What is the TAKE revenue and profit in FY26?

In FY26 (April 2025–March 2026), TAKE's consolidated net profit was ₹10.8 crore, down 71.0% from ₹37.5 crore in FY25, on revenue from operations of ₹54.2 crore.

When are the TAKE next results?

TAKE has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the TAKE shareholding pattern?

On 30 September 2026, TAKE's shares were held by foreign portfolio investors (FII/FPI) 0.21%, domestic institutions (DII) 0.00% (including mutual funds at 0.00%) and retail and other non-institutional investors 99.79%.

What is the TAKE free cash flow?

In FY26, TAKE generated ₹4.1 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹4.1 crore. In FY25 it was −₹16.4 crore.

What are the TAKE latest quarterly results?

TAKE's latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹1.1 crore, against a loss of ₹91 lakh in Q1 FY26; revenue from operations ₹30.4 crore.

How does TAKE compare with its peers?

On FY26 consolidated figures, against Suven Life Sciences: TAKE's operating margin of −3.6% is the higher of the two (Suven Life Sciences −4,077.7%; peer average −4,077.7%); its return on equity of 42.1% is the higher of the two (Suven Life Sciences −78.8%; peer average −78.8%); its revenue growth over three years of −34.1% a year is the lower of the two (Suven Life Sciences −19.3% a year; peer average −19.3% a year).

TAKE vs Suven Life Sciences: how do they compare?

In FY26, TAKE earned net profit of ₹10.8 crore on revenue of ₹54.2 crore, against ₹276 crore on ₹7.1 crore for Suven Life Sciences. TAKE's operating margin was −3.6% (Suven Life Sciences −4,077.7%) and its return on equity 42.1% (Suven Life Sciences −78.8%). At the 29 October 2026 close, TAKE's market capitalisation was ₹164 crore against ₹6,975 crore for Suven Life Sciences.

Where do these TAKE figures come from?

From TAKE's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.